Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1756286418759895 http://scihub22266oqcxt.onion/10.1177/1756286418759895 C5846919!5846919!29552092     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Neurol+Disord 2018 ; 11 (ä): ä Nephropedia Template TP {{tp|p=29552092|t=2018. Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis |pdf=|usr=}}{{29552092}} gab.com Text Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis JO: Ther Adv Neurol Disord http://www.kidney.de/pget.php?&tw=1&pmid=29552092 #FOAvip Alemtuzumab exerts its clinical efficacy by its specific pattern of depletion and repopulation of different immune cell subsets. Recently, single cases of multiple sclerosis patients who developed severe exacerbation after the first alemtuzumab application, accompanied by re-appearance of peripheral B cells, were reported. Here we present a case with underlying B cell-driven multiple sclerosis that impressively improves after alemtuzumab, although peripheral B cell repopulation took place. Our detailed clinical, histopathological, imaging and immunological data suggest that alemtuzumab can act as an effective rescue treatment in highly active B cell-driven and antibody/complement-mediated multiple sclerosis type II patients. Twit Text FOAVip Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis ????Ther Adv Neurol Disord http://www.kidney.de/pget.php?&tw=1&pmid=29552092 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29552092 #FOAvip English Wikipedia <ref>{{Cite pmid|29552092}}</ref> Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis #MMPMID29552092 Akgün K; Metz I; Kitzler HH; Brück W; Ziemssen T Ther Adv Neurol Disord 2018[]; 11 (ä): ä PMID29552092show ga Alemtuzumab exerts its clinical efficacy by its specific pattern of depletion and repopulation of different immune cell subsets. Recently, single cases of multiple sclerosis patients who developed severe exacerbation after the first alemtuzumab application, accompanied by re-appearance of peripheral B cells, were reported. Here we present a case with underlying B cell-driven multiple sclerosis that impressively improves after alemtuzumab, although peripheral B cell repopulation took place. Our detailed clinical, histopathological, imaging and immunological data suggest that alemtuzumab can act as an effective rescue treatment in highly active B cell-driven and antibody/complement-mediated multiple sclerosis type II patients. äRescue therapy with alemtuzumab in B cell/antibody-mediated multiple s(epmc).pdf DeepDyve Pubget Overpricing